AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Assetmark Inc.

Assetmark Inc. grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 5.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 227,229 shares of the company's stock after acquiring an additional 12,705 shares during the period. Assetmark Inc.'s holdings in AstraZeneca were worth $17,703,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. McClarren Financial Advisors Inc. boosted its position in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company's stock worth $25,000 after acquiring an additional 247 shares during the last quarter. GHP Investment Advisors Inc. bought a new position in AstraZeneca during the second quarter valued at approximately $26,000. Capital Performance Advisors LLP purchased a new position in AstraZeneca during the 3rd quarter valued at approximately $28,000. Pathway Financial Advisers LLC purchased a new stake in shares of AstraZeneca during the 1st quarter worth approximately $29,000. Finally, RFP Financial Group LLC grew its holdings in shares of AstraZeneca by 56.3% in the first quarter. RFP Financial Group LLC now owns 494 shares of the company's stock valued at $33,000 after purchasing an additional 178 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. TD Cowen increased their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a "buy" rating in a research report on Monday, August 12th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a "sell" rating to a "hold" rating in a research note on Wednesday, November 6th. Finally, Erste Group Bank raised AstraZeneca from a "hold" rating to a "buy" rating in a research report on Wednesday, September 11th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $89.75.

AstraZeneca Stock Performance

NASDAQ:AZN traded up $0.30 during trading hours on Monday, hitting $64.79. 7,230,333 shares of the company were exchanged, compared to its average volume of 5,206,719. The stock has a market capitalization of $200.89 billion, a price-to-earnings ratio of 31.15, a PEG ratio of 1.19 and a beta of 0.47. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. The company's 50 day moving average price is $77.07 and its 200-day moving average price is $78.62. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.